Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

• 87% of employers expect oral GLP-1s to increase demand, but only 9% predict price drops; 51% cite GLP-1s as the top driver of rising prescription drug costs
• Coverage dropped from nearly half of large employers in 2025 to 6% cutting benefits in 2026, with 5% more planning cuts for 2027 as net costs remain $569-$664 per employee monthly
• Employers are implementing stricter requirements (BMI 35+ instead of 30+), limiting coverage to diabetics only, or exploring alternative options like HRAs and third-party weight management programs to control costs

Summary: GLP-1 Weight Loss Pills Challenge Employer Insurance Coverage

Key Developments:

Novo Nordisk launched its oral GLP-1 pill Wegovy in January 2025, followed by Eli Lilly's Foundayo in April 2025. Despite hopes for lower pricing, oral versions cost essentially the same as injectables ($1,000-$1,350 list price monthly), with employers paying net prices of $569-$664 per employee monthly after discounts.

Market Impact:

Nearly half of large employers covered GLP-1 medications for weight loss in 2025, but coverage is declining. In 2026, 6% of employers with 500+ employees dropped coverage, with another 5% considering elimination for 2027. The Business Group on Health survey shows 87% of employers expect oral medications to increase demand, while only 9% anticipate price reductions. NFP's survey reveals 51% of employers cite GLP-1s as the top driver of rising prescription drug costs.

Coverage Restrictions:

Employers are tightening eligibility requirements, raising BMI thresholds from 30 to 35 or restricting coverage to diabetics only. Some may exclude oral pills entirely, as trials show they're less effective than injectables despite similar pricing.

Employee Demand:

29% of employees would switch employers for GLP-1 benefits, creating workforce retention concerns.

Alternative Solutions:

Employers are exploring health reimbursement arrangements (HRAs), third-party weight management programs, and direct-to-consumer options. Cash prices start at $149 monthly for oral GLP-1s and $199-$299 for injectables at lowest doses.

Outlook:

Federal Medicare coverage begins July 1, 2025. Prices expected to decline as competition increases, but experts warn relief remains at least a year away. Limited competition between Novo Nordisk and Eli Lilly currently constrains pricing pressure.